Warning: DOMDocument::loadHTML(): htmlParseEntityRef: no name in Entity, line: 69 in /home/dev/public_html/wp-content/themes/pru2.0/amp/single.php on line 52
Warning: DOMDocument::loadHTML(): htmlParseEntityRef: no name in Entity, line: 69 in /home/dev/public_html/wp-content/themes/pru2.0/amp/single.php on line 52
This report focuses on demand and consumption of Adenovirus Vector Vaccine in key countries, like U.S., Spain, Italy, France, UK, Germany, China and Japan, etc.
Key Findings 1: The Technology Principle of Adenovirus Vector Vaccine
Viral vector vaccine is to insert the antigen gene fragment into the gene sequence of the virus with very low pathogenicity, to infect the human body with the virus, and use human organelles to synthesize antigen, induce the immune response of the body. Due to the process of in vitro culture, isolation and purification of carrier virus, this technique is similar to that of protein subunit vaccine, but the difference is that antigen proteins are synthesized by human organelles rather than in vitro.
Get PDF report template @ https://www.qyresearch.com/sample-form/form/1662821/global-adenovirus-vector-vaccine-market
Figure 1. Figure How Viral Vector Vaccines Work
Source: https://www.dxzq.net/main/dxyj/ywfw/index.shtml?catalogId=1,8,54
Table 1. Global Representative Adenovirus Vector Vaccine Developers/Suppliers and R&D Stage
| Company | Headquarter/Country | R&D Stage |
| GREFFEX | the United States | Experiments on Animals |
| Johnson & Johnson | the United States | being developed |
| CanSino Biologics | China | Clinical II |
| Altimmune | the United States | being developed |
| University of Oxford | England | Clinical I |
| BravoBio | China | being developed |
Source: Above companies and QYResearch, 2020
Key Findings 2: The Technology Principle of Adenovirus Vector Vaccine
Among the current 70 new coronal vaccine research and development projects, about 15 of them are based on the technical route of virus vector vaccine, and about 5 of them are adenovirus vector vaccine projects. The adenovirus vector vaccine program, a collaboration between conino and the academy of military sciences, is one of the global leaders in the development of a new coronavirus vaccine. Preliminary safety data have been obtained in phase I clinical trials and subject recruitment has begun in phase II clinical trials. The ChAdOx1 programme at the university of Oxford has also been registered for a phase I clinical trial and subject recruitment has not yet begun. Clinical trials of Ad26, a collaboration between janssen and BARDA, will also begin by September. Clinical trials of the Altimmune adenovirus vector project will begin as early as this August.
Key Adenovirus Vector Vaccine Developers and Suppliers Covered in This report
l GREFFEX
l Johnson & Johnson
l CanSino Biologics
l Altimmune
l University of Oxford
l BravoBio
Key Findings 3: Clinical Trial Design of Adenovirus Vector Vaccine
Phase I of the consino adenovirus vector program was an open, dose-increasing, non-randomized controlled trial that enrolled 108 subjects in high, medium, and low dose groups for a single vaccination. The main outcome measures were adverse reactions within 7 days of inoculation. The trial will be implemented until December 31, 2020.On April 9, 2020, conino announced that it had obtained preliminary safety data in phase I clinical trials and plans to move to phase II clinical trials.500 subjects were included in the phase II clinical trial, and 250/125/125 subjects were included in the medium dose/low dose/placebo group, respectively. The main observation indicators were the titer of adverse reactions 0-14 days after inoculation and anti-novel coronavirus specific antibody 28 days after inoculation.
The vaccine developed by various technical routes has its advantages and disadvantages, and they are complementary to each other. A recombinant protein vaccine is essentially a vaccine that takes the most potent antigen component of a pathogen, the gene, and then reformulates the protein in vitro.
Get Customized Report in your Inbox within 24 hours @ https://www.qyresearch.com/customize-request/form/1662821/global-adenovirus-vector-vaccine-market
About Us:
QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.
About QY Research
QY Research is a leading global market research and consulting company. Established in 2007 in Beijing, China, QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and custom research to help our clients in providing non-linear revenue models and make them successful. We are globally recognized for our expansive portfolio of services.
